 
                Kingsley invests £10m in Oxford Cannabinoid Technologies
Kingsley Capital Partners has invested ТЃ10m in Oxford University spinout Oxford Cannabinoid Technologies (OCT), a developer of medical cannabis-based therapies.
The company will work alongside Oxford University to conduct research and development within the space.
The development comes after Kingsley founded US-based business Forma in 2016, which acquired assets across the cultivation, manufacturing and distribution of medical cannabis. Kingsley managing partner Neil Mahapatra is the president of Forma.
Company
OCT is a therapeutic cannabinoid biotechnology company. The business will develop therapies for acute and chronic conditions including pain, cancer, neurological disorders and inflammatory disease.
People
Kingsley Capital Partners – Neil Mahapatra (managing partner).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









